Drug Profile


Alternative Names: AL-6515; Ilevro; Nepafenac ophthalmic suspension 0.1% - Alcon; Nevanac

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alcon
  • Class Analgesics; Aniline compounds; Anti-inflammatories; Benzeneacetamides; Benzophenones; Eye disorder therapies; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain; Retinal oedema
  • Phase III Diabetic retinopathy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 May 2017 The Scottish Medicines Consortium approves nepafenac for the reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients
  • 01 May 2015 Alcon Research completes the study 1 phase III trial in Diabetic retinopathy in USA (NCT01853072)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top